Latest1 information on COVID-19
©2022 Stanford Medicine
Not Recruiting
Trial ID: NCT01741545
A Phase 3 Study Evaluating the Safety and Efficacy of Lambda/Ribavirin/Daclatasvir in Subjects With Chronic HCV Infection and Underlying Hemophilia Who Are Treatment Naïve or Are Prior Relapsers to Peginterferon Alfa-2a/Ribavirin
Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health
For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com.
Inclusion Criteria:
- Severe hemophilia (defined as < 1% factor activity level)
- Infection with the hepatitis C virus (HCV) with underlying hemophilia
- Males 18 years of age and above
- Have not been previously treated with an interferon
Exclusion Criteria:
- Not infected with the hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
- Chronic liver disease caused by any disease other than chronic HCV infection
- Presence of Bethesda inhibitor
- Current evidence of or history of portal hypertension
biological: Pegylated-Interferon-lambda
drug: Ribavirin
drug: Daclatasvir
Not Recruiting
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Mindie H. Nguyen, MD
650-498-7878